You are here

Article Text

Article menu
Download PDFPDF
Case Reports: Adverse drug reactions and complications
Gross hematuria secondary to use of carboplatin in neoadjuvant treatment of breast cancer with HER2 overexpression
  1. Julia Pastorello1,2,
  2. Nicolas Almeida Leal da Silva3,
  3. Natalia Bassani Schuch4 and
  4. Emanuela Lando2
  1. 1Department of Clinical Oncology, Hospital de Clínicas de Passo Fundo - HCPF, Passo Fundo, Rio Grande do Sul, Brazil
  2. 2Academic League of Oncology and Hematology - LAONC - HCPF, Hospital de Clínicas de Passo Fundo - HCPF, Passo Fundo, Rio Grande do Sul, Brazil
  3. 3Department of Urology, Hospital de Clínicas de Passo Fundo - HCPF, Passo Fundo, Rio Grande do Sul, Brazil
  4. 4Department of Nephrology, Hospital de Clínicas de Passo Fundo - HCPF, Passo Fundo, Rio Grande do Sul, Brazil
  1. Correspondence to Professor Julia Pastorello; Julia.pastorello{at}yahoo.com.br

Abstract

Breast cancer is a high prevalent neoplasia in women worldwide, and platinum compounds are widely used to treat it. On rare occasions, macroscopic hematuria associated with carboplatin has been identified. Thus, the present study aims to report a rare case of a female patient diagnosed with invasive ductal carcinoma, which presented hematuria secondary to carboplatin, showing improvement of the condition after 4 days of expectant treatment with clot lavage. Due to the scant description of hematuria secondary to carboplatin in the scientific literature, it is essential to report such case in order to assist and enrich the understanding of this event.

  • Breast cancer
  • Chemotherapy
  • Hematuria
  • Oncology

https://doi.org/10.1136/bcr-2021-245407

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors JP was the primary physician of the patient involved in the treatment and critical revision of the article. JP and EL were involved in collection and/or assembly of data. All authors (JP, NALdS, NBS and EL) were involved in research concept and design, data analysis and interpretation, manuscript writing, final approval of the article and in agreement to be accountable for the article and to ensure that all questions regarding the accuracy of the article are investigated and resolved.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.